Purchase this article with an account.
T. Evans, F. Arevalo, M. Berrocal, F. Rodriguez, M. Hsu, J. Sanchez, S. Iturriaga, L. Wu; The Effect of an Intravitreal Triamcinolone Injection in Macular Edema Secondary to Parafoveal Telangiectasis Type 2A . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4253.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the visual outcome and ocular complications of an intravitreal injection of triamcinolone (IVT) in the treatment of macular edema secondary to parafoveal telangiectasis (PFT) type 2A.
Multicenter retrospective case series of 19 eyes from 14 patients with macular edema secondary to PFT type 2A that had undergone an intravitreal injection of 4 mg of triamcinolone.
At baseline, 5.3% (1/19) had a visual acuity of 20/40 or better, 47.3% (9/19) between 20/50, and 20/160, 47.3% (9/19) worse than 20/200. Patients were followed for an average of 17.3 months (range 5–32 months). At the last follow up after IVT, 31.6% (6/19) improved 2 or more lines of vision, 57.9% (11/19) remained within 2 lines of baseline visual acuity, 10.5% (2/19) lost 2 or more lines of vision. In addition, 16% (3/19) had 20/40 or better, 42% (8/19) had between 20/50 and 20/160, and 42% (8/19) had 20/200 or worse. Seven eyes were reinjected once. No cases of retinal detachment, vitreous hemorrhage or endophthalmitits were reported. However 53% (10/19) developed cataract (one case required phacoemulsification and intraocular lens implantation) and 21% (4/19) had an elevated intraocular pressure, none of which required surgical treatment.
Intravitreal triamcinolone does not seem to have a long term beneficial effect in most eyes with macular edema secondary to PFT type 2A.
This PDF is available to Subscribers Only